Variable | HCV treatment subset | P Value | |
---|---|---|---|
 | No (n = 94) | Yes (n = 32) |  |
Gender: | Â | Â | Â |
   Female | 14 | 7 | 0.56 |
   Male | 79 | 25 |  |
Race/ethnicity: | Â | Â | Â |
   White | 55 | 11 | 0.09 |
   Hispanic | 20 | 9 |  |
   Black | 17 | 10 |  |
   Unknown/other | 2 | 2 |  |
Race/ethnicity, dichotomized: | Â | Â | Â |
   White | 55 | 11 | 0.02 |
   Non-white | 39 | 21 |  |
HIV risk factor: | Â | Â | Â |
   Gay/bisexual | 34 | 13 | 0.96 |
   Heterosexual | 11 | 3 |  |
   Intravenous drug use | 39 | 13 |  |
   Hemophiliac | 1 | 0 |  |
   Unknown/other | 0 | 3 |  |
CD4 cell count (×106/l), mean (sd) | 488(294) | 478(272) | 0.61 |
HIV log10 viral load, mean(sd) | 2.12(0.96) | 1.66(0.07) | 0.01 |
HCV log10 RNA, mean (sd) | 6.36(1.30) | 6.27(1.12) | 0.63 |
HCV genotype: | Â | Â | Â |
   Genotype 2 & 3 | 14 | 6 | 0.65 |
   Genotype 1 & 4 | 74 | 25 |  |
History of neuropsychiatric disease (%) | 56 (60) | 18 (56) | 0.74 |
Ever use illicit substance (%) | 87 (93) | 28 (88) | 0.38 |
Ongoing illicit substance use (%) | 12 (13) | 3 (9) | 0.61 |
Total symptoms score, mean (sd) | 73(25) | 56(10) | 0.002 |
Neuropsychiatric symptoms score, mean(sd) | 28(11) | 19(4) | 0.00006 |
Somatic symptoms score, mean (sd) | 19(8) | 16(5) | 0.0001 |
Sleep symptoms score, mean (sd) | 4(3) | 3(2) | 0.04 |
CES-D score, mean (sd) | 17(13) | 8(7) | 0.00003 |